WASHINGTON D.C. (December 8, 2023) — Keren Haruvi today was announced as the new chairperson of the Board of Directors of the Association for Accessible Medicine. She is President of Sandoz North America and most recently served as Vice Chair of the Board of AAM.
Haruvi succeeds Christine Baeder, who recently left her position as Senior Vice President, Chief Operating Officer US Generics and Global Biosimilars at Teva Pharmaceuticals USA, Inc. As vice chair, Haruvi becomes chair for the remainder of the term until the next election of the board of directors.
I want to thank Christine for her hard work and strong advocacy on behalf of patients and our industry, said Keren Haruvi, Chairperson of the AAM Board of Directors.
We will continue to focus on the incredible value generic medications and biosimilars provide to patients and the overall health care system. Over 90% of all prescriptions filled in the US are generics or biosimilars, yet we are constantly up against a system that is not properly designed or modernized for a robust supply chain or open marketplace for patients to have access to the medications they need.
David Gaugh, Interim CEO and President of AAM stated,
As a board member, Keren has done great work for AAM member and is certain to do even more so as our new chairperson. AAM will continue to shine a light on the great work of our member companies and advocate on behalf of the industry on ways we can improve the health care ecosystem to better serve patients across the country. We are all grateful for the foundation Christine built during her tenure and wish her all the best for the future.
Prior to her current role at Sandoz, Haruvi served as Global Head of M&A for Novartis after 14 years at Teva Pharmaceuticals.
For media inquiries, contact the Communications department at email@example.com.
AAM is driven by the belief that access to safe, quality, effective medicine has a tremendous impact on a person’s life and the world around them. Generic and biosimilar medicines improve people’s lives, improving society and the economy in turn. AAM represents the manufacturers and distributors of finished generic pharmaceuticals and biosimilars, manufacturers and distributors of bulk pharmaceutical chemicals, and suppliers of other goods and services to the generic industry. Generic pharmaceuticals are 90 percent of prescriptions dispensed in the U.S. but only 17.5 percent of total drug spending.
About the Biosimilars Council
The Biosimilars Council, a division of the Association for Accessible Medicines (AAM), works to ensure a positive environment for patient access to biosimilar medicines. The Biosimilars Council is a leading source for information about the safety and efficacy of more affordable alternatives to costly brand biologic medicines. Areas of focus include public and health expert education, strategic partnerships, government affairs, legal affairs and regulatory policy. More information is available at www.biosimilarscouncil.org.